Recent Lassa fever outbreaks in Africa show vital need for new products that can be processed in any clinical or field lab
DENVER and NEW ORLEANS, May 7 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an extension of the collaborative effort for developing test kits for the detection of viral hemorrhagic fever (VHF).
The National Institutes of Health (NIH) has awarded a five-year grant to
"We are extremely pleased to be part of this collaboration and to have received the NIH grant," said Douglass Simpson, Corgenix President and CEO. "We have made major strides in the development and clinical study phases and this will enable us to further develop the assays, complete the clinical studies and achieve full commercialization."
This is the second grant awarded to
Joseph Fair, Ph.D., MPH, Director, Global Field Operations, Global Viral Forecasting Initiative, San Francisco, a consultant to the Lassa group, noted, "these recombinant-based serological assays designed for field deployment offer the public health and scientific communities a powerful tool to accurately assess the true disease burden and risks posed by Lassa and other especially dangerous pathogens, while collaterally improving upon their treatment and ultimately prevention."
Lassa fever, a serious viral disease spread by contact with infected rodents, is estimated to infect 300,000 to 500,000 people per year across West Africa, with approximately 5,000 deaths. In some areas of Sierra Leone and Liberia, up to 16 percent of people admitted to hospitals have Lassa fever. Lassa fever is also associated with occasional epidemics, during which the case-fatality rate can reach 50 percent.
New outbreaks of the Lassa fever have been reported recently, including in Nigeria. Daniel Bausch, M.D., MPH&TM, Director of Tulane's Research and Training Program in West Africa, observed, "We are now seeing much broader presence of this disease in Africa. Within the past year alone we have seen a significant increase in the number of cases in Nigeria, with increased fatalities. It is critical that the assays we have already developed and are using in Africa, as well as others still in our development pipeline, become fully deployed to aid in this vital effort."
Under the NIH grant,
Robert Garry, Ph.D., Professor of Microbiology and Immunology at the
Dr. Garry stated that the group intends to expand this program to address other important infectious agents--such as Ebola, Marburg and other hemorrhagic fever viruses--that are of concern to the public health and bioterrorism preparedness communities.
About Corgenix Medical Corporation
Corgenix (Denver, Colo.) is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
About Tulane University
About Autoimmune Technologies, LLC
Autoimmune Technologies (New Orleans, La.) is a privately held biomedical company. It has licensed several breakthrough research discoveries from
About Vybion, Inc.
Vybion (Ithaca, N.Y.) is an emerging biotechnology company with a proprietary biopharmaceutical drug pipeline and platform technology for human monoclonal antibody selection and affinity maturation. The company's contract division has developed over 150 recombinant proteins in multiple expression systems including 12 biologic drugs in various phases of clinical development.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
|SOURCE Corgenix Medical Corporation|
Copyright©2009 PR Newswire.
All rights reserved